Merck Sharp + Dohme Corp.

Richard C A Isaacs

Joseph P Vacca

John S Wai

Linda S Payne

Mark T Bilodeau

Zhicai Wu

Peter D Williams

B Wesley Trotter

Shankar Venkatraman

Wayne J Thompson

Dai-Shi Su

Peter Emmanuel Maligres

Mark W Embrey

Zhiguo Jake Song

Thorsten E Fisher

Jacob M Hoffman

Tao Pei

Jingjun Yin

David C Dubost

Neil A Strotman

Michael Shevlin

Richard Pracitto

Richard G Ball

Dietrich P Steinhuebel

Matthew L Maddess

Ahren Iver Green

Eric J Choi

Neil Campbell

Sarah L Trice

Matthew Maddess

Wei Han

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X, X, Y, R, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.

HIV integrase inhibitors

The present invention relates to dipyridin-3-ylmethoxy compounds and derivatives thereof having the structure I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. 

Potassium channel inhibitors

Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

Growing community of inventors

Harleysville, PA, United States of America

Richard C A Isaacs